{{Use mdy dates|date=August 2010}}
{{Drugbox
| verifiedrevid = 458267412
| IUPAC_name = (''RS'')-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1''H''-benzo[''d'']imidazole
| image = Lansoprazole.svg
| width = 200px
| image2 = Lansoprazole 3D.png
| imagename = 1 : 1 mixture (racemate)
| drug_name = Lansoprazole

<!--Clinical data-->
| tradename = Prevacid
| Drugs.com = {{drugs.com|monograph|lansoprazole}}
| MedlinePlus = a695020
| licence_US = Lansoprazole
| pregnancy_AU = B3
| pregnancy_US = B
| legal_US = OTC
| legal_UK = POM
| routes_of_administration = Oral, [[intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability = 80% or more
| protein_bound = 97%
| metabolism = [[Liver|Hepatic]] ([[CYP3A4]]- and [[CYP2C19]]-mediated)
| elimination_half-life = 1–1.5 hours
| excretion = [[Kidney|Renal]] and [[feces|fecal]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 103577-45-3
| ATC_prefix = A02
| ATC_suffix = BC03
| PubChem = 3883
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00448
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3746
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0K5C5T2QPG
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00355
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6375
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 480

<!--Chemical data-->
| C=16 | H=14 | F=3 | N=3 | O=2 | S=1 
| molecular_weight = 369.363 g/mol
| smiles = FC(F)(F)COc1c(c(ncc1)CS(=O)c3nc2ccccc2n3)C
| InChI = 1/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
| InChIKey = MJIHNNLFOKEZEW-UHFFFAOYAS
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MJIHNNLFOKEZEW-UHFFFAOYSA-N
}}
'''Lansoprazole''' ({{IPAc-en|icon|l|æ|n|ˈ|s|oʊ|p|r|ə|z|oʊ|l}} {{respell|lan|SOH|prə-zohl}}; [[International Nonproprietary Name|INN]]) is a [[proton-pump inhibitor]] (PPI) which inhibits the [[stomach]]'s production of [[gastric acid]]s. It is manufactured by a number of companies worldwide under several [[#Brand names|brand names]]. In the United States it was first approved by the [[Food and Drug Administration (United States)|Food and Drug Administration]] (FDA) in 1995.<ref name="Mosby's">[http://www.mosbysdrugconsult.com/DrugConsult/Top_200/Drugs/e3230.html Mosby's Drug Consult: Lansoprazole]</ref>

Lansoprazole has been available as a [[generic drug]] since Prevacid patent protection expired on November 10, 2009.<ref>[http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=PREVACID&archive=2008 Prevacid drug patents]</ref><ref name="Teva">[http://www.marketwatch.com/story/teva-to-release-prevacid-version-when-patent-expires Teva to release Prevacid version when patent expires]</ref> Since 2009 Lansoprazole has been available over the counter (OTC) in the U.S. in a 15&nbsp;mg dose marketed by [[Novartis]] as '''Prevacid 24HR'''.<ref>
{{cite press release
 | url=http://www.prevacid24hr.com/pdfs/News%20media%20release%20-%20Prevacid24HR%20Launch%20-%20November%202009.pdf
 | title=Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment
 | date=November 12, 2009
 | format=PDF
 | accessdate = 2009-11-13
}}</ref><ref>
{{cite web
 | url=http://www.prevacid24hr.com/pdfs/PackageInsert.pdf
 | title=Prevacid 24HR Patient Package Insert
 | date=November 12, 2009
 | format=PDF
 | accessdate = 2009-11-13
}}</ref><ref>
{{cite press release
 | url=http://www.novartis.com/newsroom/media-releases/en/2009/1354451.shtml
 | title=Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment
 | date=November 12, 2009
 | accessdate = 2009-11-13
}}</ref>

{{Main|Proton-pump inhibitor}}
Lansoprazole is a [[proton-pump inhibitor]] (PPI) in the same pharmacologic class as [[omeprazole]].  Lansoprazole has been marketed for many years and is one of several PPIs available.<ref>http://www.patient.co.uk/showdoc/30002943/</ref> Lansoprazole is a racemate [1:1-mixture of the [[enantiomer]]s [[dexlansoprazole]] (Kapidex) and levolansoprazole].<ref>http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf {{dead link|date=June 2012}}</ref> Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,<ref name="RxList">{{cite web | url = http://www.rxlist.com/cgi/generic/lansop_cp.htm | title = Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism | year = 2007 | accessdate = 2007-04-14 | publisher = RxList.com}}</ref> and the effects of the drug last for over 24 hours after it has been used for 1 day or more.<ref>
{{cite web
 | url=http://www.prevacid24hr.com/pdfs/Prevacid24HR_Product_Fact_Sheet.pdf
 | title=Prevacid 24HR Fact Sheet
 | date=November 12, 2009
 | format=PDF
 | accessdate = 2009-11-13
}}</ref> Lansoprazole, 30&nbsp;mg administered [[Nasogastric intubation|nasogastrically]], effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.<ref>[http://www.richmondpharmacology.com/downloads/Publications/Effects%20on%2024-Hour%20Intragastric%20pH%20A%20Comparison%20of%20Lansoprazole%20Administered.pdf Effects on 24-Hour Intragastric pH]{{cite journal|last=Freston M.D., Ph.D.|first=James|coauthors=Yi-Lin Chiu, Ph.D., Wei-Jian Pan, Ph.D., Nancy Lukasik, B.S.N., and Jörg T&#228;ubel, M.D., A.F.P.M.|title=Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously|year=2001|journal=American Journal of Gastroenterology|volume=96|issue=7|pages=2058–2065|issn=0002-9270|pii=S0002-9270(01)02502-3|oclc=440925790|doi=10.1111/j.1572-0241.2001.03939.x|pmid=11467632}}</ref>

==Indications==
{{Unreferenced section|date=November 2009}}
Lansoprazole is indicated for:
*Treatment of [[Peptic ulcer|ulcers]] of the stomach and [[duodenum]], and [[NSAID]]-induced ulcers.
*Adjunctive treatment of ''[[Helicobacter pylori]]'' infection, alongside [[antibiotics]]. Treatment to kill Helicobacter pylori (H. pylori) causing ulcers or other problems involves using two other drugs besides lansoprazole. This treatment is known as "[[Helicobacter pylori eradication protocols|triple therapy]]", and involves taking twice daily for 10 or 14 days lansoprazole 30&nbsp;mg, amoxicillin 1,000&nbsp;mg, and clarithromycin 500&nbsp;mg.
*Treatment of [[gastroesophageal reflux disease]] (GERD) (also known as ''acid reflux disease'').
*Treatment of [[Zollinger-Ellison Syndrome]].

==Drug interactions==
Lansoprazole interacts with several other drugs, either due to its own nature or as a proton pump inhibitor.<ref>[http://bnf.org/bnf/bnf/current/41001i753.htm British National Formulary] (Free registration required) Lansoprazole interactions</ref>
*PPIs reduce absorption of [[Antifungal drug|antifungals]] ([[itraconazole]] and [[ketoconazole]]) <ref>Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC245265/]</ref> and possibly increase [[Digoxin]] in plasma
*Increases plasma concentrations of [[Cilostazol]] (risk of toxicity)
*Lansoprazole possibly interacts with, amongst other drugs:
** [[sucralfate]]
** [[ampicillin]]
** [[bisacodyl]]
** [[clopidogrel]]
** [[delavirdine]]
** [[fluvoxamine]]
** iron salts
** [[voriconazole]]
** [[aminophylline]] and [[theophylline]]
** [[astemizole]]

==Side effects==
Side effects of proton pump inhibitors in general<ref>[http://bnf.org/bnf/bnf/current/2137.htm#_200909 British National Formulary] (Free registration required) 1.3.5 Proton pump inhibitors</ref> and lansoprazole in particular<ref>[http://bnf.org/bnf/bnf/current/129429.htm#_129429 British National Formulary] (Free registration required) Lansoprazole</ref> may include:
*'''Infrequent''': [[dry mouth]], [[insomnia]], [[drowsiness]], blurred [[Visual perception|vision]], [[rash]], [[pruritus]]
*'''Rarely and very rarely''': [[taste]] disturbance, [[liver]] dysfunction, [[oedema|peripheral oedema]], hypersensitivity reactions (including [[bronchospasm]], urinary, [[angioedema]], [[anaphylaxis]]), [[photosensitivity]], [[fever]], [[sweating]], [[clinical depression|depression]], [[interstitial nephritis]], blood disorders (including [[leukopenia]], [[leukocytosis]], [[pancytopenia]], [[thrombocytopenia]]), [[arthralgia]], [[myalgia]], skin reactions<ref>K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225</ref> including ([[erythroderma]]<ref name="bolognia">{{cite book |author=Sterry W, Assaf C |chapter=Erythroderma |editor=Bolognia JL |title=Dermatology |publisher=Mosby |location=St. Louis |year=2007 |page=154 |isbn=1-4160-2999-0}}.</ref> [[Stevens–Johnson syndrome]], [[toxic epidermal necrolysis]], [[blister|bullous eruption]])
*'''Severe''': Gastro-intestinal disturbances (such as [[nausea]] 1.3%, [[abdominal pain]] 2.1%, [[diarrhea]] 3.8%).<ref name="RxList">{{cite web | url = http://www.rxlist.com/cgi/generic/fluoxetine_cp.htm | title = Prozac Pharmacology, Pharmacokinetics, Studies, Metabolism | year = 2007 | accessdate = 2007-04-14 | publisher = RxList.com}}</ref>

Proton-pump inhibitors may be associated with a greater risk of hip fractures<ref name="JAMA">
{{cite journal
| author = Yang YX, Lewis JD, Epstein S, Metz DC
| title = Long-term proton pump inhibitor therapy and risk of hip fracture
| journal = [[JAMA (journal)|JAMA]]
| volume = 296
| issue = 24
| pages = 2947–53
| year = 2006
| month = December
| pmid = 17190895
| doi = 10.1001/jama.296.24.2947
}}</ref> and ''[[Clostridium difficile]]''-associated diarrhea.<ref name="Bandolier">{{cite web | url = http://www.medicine.ox.ac.uk/bandolier/booth/Pharmacy/PPIcdiff.html | title = Proton pump inhibitors and Clostridium difficile | year = 2003 | accessdate = 2007-07-13 | publisher = Bandolier}}</ref> Antacid preparations such as lansoprazole by suppressing acid mediated break down of proteins, leads to an elevated risk of developing food and drug allergies. This happens due to undigested proteins then passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well.<ref name="pmid21121928">{{cite journal |author=Pali-Schöll I, Jensen-Jarolim E |title=Anti-acid medication as a risk factor for food allergy |journal=Allergy |volume=66 |issue=4 |pages=469–77 |year=2011 |month=April |pmid=21121928 |doi=10.1111/j.1398-9995.2010.02511.x |url=}}</ref> Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.<ref name="JAMA2">
{{cite journal
| author = Herzig SJ, Howell MD, Ngo LH, Marcantonio ER
| title = Acid-suppressive medication use and the risk for hospital-acquired pneumonia
| journal = [[JAMA (journal)|JAMA]]
| volume = 301
| issue = 20
| pages = 2120–8
| year = 2009
| month = May
| pmid = 19470989
| doi = 10.1001/jama.2009.722
}}</ref>

== Brand names ==
[[Image:prevacid30mg.png|thumb|Prevacid 30&nbsp;mg]]
Lansoprazole is available as a [[generic drug]] in the US, Russian Federation, UK, Canada, Belgium, Finland,<ref>{{cite web
| url = http://www.terveyskirjasto.fi/terveysportti/geneerinen.substituutio?p_ryhma=0000130030
| title = Vastaavat tuotteet - hintavertailu
| language = Finnish
}}</ref> France, Colombia, Italy, Sweden,<ref>{{cite web
| url = http://www.fass.se/LIF/produktfakta/substance_products.jsp?substanceId=IDE4POFNUB4MJVERT1
| title = FASS.se, accessed 2010-02-13
| language = Swedish
}}</ref> and Mexico.{{Citation needed|date=November 2009}}

The drug is also sold under several brand names, including:<ref name="Mosby's" />
* '''Agopton''' (Germany)
* '''Digest''' (Indonesia)
* '''Duogast''' (Syria)
* '''GERD''' (Pakistan)
* '''Gastrolan''' (Indonesia)
* '''Lanciprol''' (Greece)
* '''Lansazol''' (Jordan)
* '''Lansobene''' (Austria)
* '''Lansoloc''' (South Africa)
* '''Lansoprazol''' (Denmark)
* '''Lansoptol''' (Hungary)
* '''Lansor''' (Turkey)
* '''Lansox''' (Italy)
* '''Lanston LFDT''' (South Korea)
* '''Lenzo''' (India)
* '''Lanzol''' (India, Ireland)
* '''Lanzotec''' (Jordan)
* '''Lanzul''' (Romania/Slovenia)
* '''Lanton''' (Israel)
* '''Lanzo''' (Sweden)
* '''Lanzopral''' (Argentina, Chile, Peru, Venezuela[http://www.drugs.com/international/lansoprazole.html])
* '''Lanzor''' (France, South Africa)
* '''Lanzostad''' (Lithuania, Latvia, Estonia)
* '''Laprazol''' (Greece)
* '''Limpidex''' (Italy)
* '''Monolitum''' (Spain)
* '''Ogast''' and '''OgastORO''' (France)
* '''Ogastro''' (Mexico)
* '''Prevacid''' (U.S. and Canada)
* '''Prosogan''' and '''Prosogan FD''' (Indonesia)
* '''pro-ulco''' (Spain)
* '''Refluxon''' (Hungary)
* '''Sabax''' (Serbia)
* '''SOLOX''' (New Zealand)
* '''Takepron''' (Japan)
* '''Zolt''' (Finland)
* '''Zoton''' (Italy, Ireland, Australia, UK)
* '''ZOMEL''' (Ireland)
* '''Lanzap''' (Romania)
* '''Levant''' (Romania)
* '''Lantrea''' (Poland)

== References ==
{{Reflist|2}}

== External links ==
* [http://www.prevacid.com/products.aspx Prevacid official website] Takeda Pharmaceuticals North America
* [http://www.prevacid24hr.com/ Prevacid 24HR official website] Novartis Consumer Health
* [http://www.prevacid.com/products/prevpac-ulcer-treatment.aspx Prevpac official website] Takeda Pharmaceuticals North America
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Lansoprazole U.S. National Library of Medicine: Drug Information Portal - Lansoprazole]

{{Proton-Pump Inhibitors}}

[[Category:Proton pump inhibitors]]
[[Category:Benzimidazoles]]
[[Category:Sulfoxides]]
[[Category:Pyridines]]
[[Category:Phenol ethers]]
[[Category:Organofluorides]]